Factors associated with prolonged hospital stay in patients with autoimmune bullous diseases treated at an in-patient dermatology service Authors: Pedro Juan Saldarriaga-Muñoz, Valentina Rodelo-Sánchez, Isabela Agudelo-Aguilar, David Osorio-Álvarez, Sebastián Valencia-Montoya, Sebastián Bedoya-Mejía, Susana Chiquito-García, Geovanna Andrea Ayala-Monroy Published: 2026 ABSTRACT AbstractBackgroundBullous diseases carry a great burden and are often linked to high healthcare costs. Patients with ­bullous diseases are more vulnerable to infections and organ damage due to an incompetent skin barrier.ObjectivesTo determine the demographic, clinical and laboratory factors associated with prolonged hospital stay in patients with autoimmune bullous diseases.MethodsThis was a cross-sectional study, with a follow-up cohort, including all dermatology consultations in a university hospital between 2017 and 2022 to identify patients with autoimmune bullous disease. Duration of stay and other variables were obtained from the patients’ medical records.ResultsA total of 83 patients were included in the study, of whom the majority had bullous pemphigoid (n = 45; 54%). There was significant metabolic comorbidity with hypertension (n = 51; 61%), diabetes (n = 31; 37%) and dyslipidaemia (n = 31; 37%). Fifty-eight per cent of patients had a prolonged hospital stay (>10 days). Among the associated variables, mucosal involvement, eosinophilia, in-hospital antibiotics and the absence of dipetidyl peptidase-4 (DPP4) inhibitor use stood out.ConclusionsMost patients with bullous diseases have prolonged hospital stays. The evaluation of mucous membranes, blood count and a basic chemical panel can help identify patients at greater risk of prolonged hospital stays. In addition, the use of DPP4 inhibitors and their rapid discontinuation could affect this outcome. Bullous diseases have a great disease burden and are often linked with high healthcare costs. Bullous diseases have a great disease burden and are often linked with high healthcare costs. These patients are more vulnerable to infections and organ damage due to skin barrier damage. These patients are more vulnerable to infections and organ damage due to skin barrier damage. A thorough evaluation of comorbidities and medical treatments can identify factors associated with prolonged hospital stay. A thorough evaluation of comorbidities and medical treatments can identify factors associated with prolonged hospital stay. Clinical and laboratory analysis may also contribute to the identification of patients at risk of having a prolonged hospital stay. Clinical and laboratory analysis may also contribute to the identification of patients at risk of having a prolonged hospital stay. Autoimmune bullous diseases (AIBDs) are characterized by the development of flaccid or tense blisters depending on the level of immune involvement in the epidermis or dermoepidermal junction.1 Although their presentation is varied, they commonly affect the adult population, especially those over 50 years of age, with various comorbidities including hypertension, diabetes and neuropsychiatric diseases.1,2 In the USA, the prevalence of hospitalizations associated with just one of these diseases, bullous pemphigoid (BP), increased from 25.84 to 32.60 cases per million between 2002 and 2012.3 Ren et al. have described an average hospital stay of 7.3 days in the same period.3 This goes hand in hand with a higher number of infections and chronic comorbidities, as well as an average ­in-hospital mortality rate of 2.9%, raising the costs of care.3,4 Although they are diseases associated with a considerable disease burden, there is no extensive information on the factors associated with prolonged hospital stay. This is important as a prolonged hospital stay carries with it an increased risk of infectious and thrombotic complications, among others, in addition to an increase in the costs associated with the disease.4 On the contrary, most studies have focused on identifying factors associated with mortality.5,6 This is especially true in the Latin American context, where most studies have focused on the characterization of patients with these diseases without analysing associated clinical outcomes.7 As such, the objective of this study was to determine the demographic, clinical and laboratory factors associated with prolonged hospital stay in patients with AIBDs treated in an in-patient dermatological institution in Medellín, Colombia, from January 2017 to December 2022. Patients and methods This cross-sectional study followed a cohort of patients treated between 1 January 2017 and 31 December 2022 at an institution with an in-patient dermatology service that treats an average of 700 patients annually and has more than 40 years of experience. The medical records of all patients aged >18 years with bullous diseases seen during this period were evaluated, excluding pregnant patients and patients referred to other institutions during hospitalization. More than 3000 patients seen at the dermatology service over the course of the 5-year study period were considered potentially eligible for inclusion. Each patient was evaluated from the day of admission to hospital until their discharge from the institution. The primary outcome was the duration of hospital stay (days) from admission until discharge. Based on a literature review, a duration of >10 days was used as the cutoff point for a prolonged hospital stay.8–10 We recorded patient variables such as demographic factors, clinical history and comorbidities; clinical findings such as affected body surface area and mucosal involvement; pathology findings such as blister level and infiltrate density; and laboratory findings such as blood count, kidney function and liver enzymes. These variables were considered as each of these may play a role in establishing greater prior frailty, more extensive disease involvement, greater inflammatory status and associated organ damage, all factors that can lead to longer hospital stays. Data collection was carried out by four of the researchers; a pilot trial was carried out with the first 10 patients to standardize this process and avoid information biases. Demographic, clinical and laboratory data were taken directly from clinical records, while the pathology data were obtained from official reports issued by the dermatopathology service to avoid biases caused by the interpretation of findings by the treating dermatologist. Vital signs were obtained from nursing records, and laboratory reports directly from the internal record included in the medical record service. For the qualitative variables, frequency tables were used, and their confidence intervals (CIs) were accompanied by a proportion. For quantitative variables, assumption of normality was verified by the Shapiro–Wilk statistical test, and measures of central tendency and dispersion are shown as appropriate. Likewise, for the bivariate analysis, a χ2 statistical test of independence and Fisher’s exact test were used. Crude prevalence ratios were calculated accompanied by their CI as an epidemiological measure. Binomial regression with log link was performed, showing adjusted prevalence ratios, as well as all those that met the Hosmer and Lemeshow criteria, which were statistically significant (P < 0.05), and were plausible. An interdependence analysis was carried out to identify multiple correspondence to create the profile of patients with prolonged and nonprolonged stays. Results Demographics A total of 3000 records were evaluated from which 83 patients with AIBDs were identified, with a 2.8% prevalence. Of the 83 patients, 51 (61%) were women. The median age was 75 years (interquartile range 61–82). The most common diagnosis was BP (n = 45; 54%). Thirty-one per cent (n = 26) had recently started medications, of which the use of dipetidyl peptidase-4 (DPP4) inhibitors, diuretics and antibiotics stood out. The most frequent comorbidities were hypertension (n = 51; 61%), diabetes (n = 31; 37%) and dyslipidaemia (n = 31; 37%). There was oral mucosal involvement in 28% (n = 23) and scalp involvement in 25% (n = 21) of patients. Records showed leucocytosis in 70% (n = 58), anaemia in 33% (n = 27), eosinophilia in 33% (n = 27), hyperglycaemia in 31% (n = 26) and elevated creatinine in 30% (n = 25) (Tables 1, 2). Table 1Qualitative characteristics of 83 patients with bullous diseases who were treated in hospitalVariable n (%)95% CIClinical variables Sex Female51 (61)43–72 Male32 (39)28–49 Recent use of prescription drugs Recent use of prescription drugs26 (31)21–41 DPP4 inhibitors10 (12)5–19 Diuretics10 (12)5–19 Antibiotics14 (17)9–25 Anticonvulsive3 (4)0–8 NSAID3 (4)0–8 Opioids2 (2)0–6 Medical history Neoplasia5 (6)1–11 Haematological malignancy2 (2)0–6 Solid organ malignancy4 (5)0–9 Recent infection16 (19)11–28 Chronic hypertension51 (61)51–72 Diabetes mellitus31 (37)27–48 Hypothyroidism11 (13)6–21 Dyslipidaemia31 (37)27–48 Obesity24 (29)19–39 Neurological disease24 (29)19–39 Psychiatric disease20 (24)15–33 Autoimmune disease5 (6)1–11 Type of bullous disease Bullous pemphigoid45 (54)44–65 Foliaceus pemphigus13 (16)8–24 Vulgar pemphigus19 (23)14–32 IgA pemphigus2 (2)0–6 Acquired epidermodysplasia bullosa1 (1)0–4 Herpetiform dermatitis0 (0)0–0 Linear IgA dermatosis2 (2)0–6 Bullosis diabeticorum1 (1)0–4 Bullous lupus erythematosus0 (0)0–0 Special area involvement Scalp21 (25)16–35 Oral mucosa23 (28)18–37 Conjunctiva3 (4)0–7.6 Genital mucosa6 (7)2–13Laboratory variables Anaemia No anaemia55 (66)56–76 Anaemia27 (33)23–43 No information1 (1)1–4 Leucocyte count Leucopenia4 (5)0–9 Normal range20 (24)15–33 Leucocytosis58 (70)60–80 No information1 (1)1–4 Eosinophil count Normal range49 (59)49–70 Eosinophilia27 (33)23–43 No information7 (8)3–14 Creatinine Normal range56 (67)57–78 Elevated25 (30)20–40 No information2 (2)1–6Treatment variables Topical steroids High potency34 (41)30–52 Medium potency38 (46)35–57 Low potency2 (2)0–6 Not prescribed9 (11)2–13 Systemic steroids 0–10 mg2 (2)0–6 >10–20 mg5 (6)1–11 >20–50 mg49 (59)49–70 >50 mg22 (27)17–36 Not prescribed5 (6)1–11 Opioids No67 (81)69–87 Yes16 (19)11–28 Antibiotics No56 (67)55–75 Yes27 (33)23–43 Duration of hospital stay Not prolonged35 (42)32–53 Prolonged48 (58)47–69CI, confidence interval; DPP4, dipeptidyl peptidase-4; NSAID, nonsteroidal anti-inflammatory drug. Qualitative characteristics of 83 patients with bullous diseases who were treated in hospital CI, confidence interval; DPP4, dipeptidyl peptidase-4; NSAID, nonsteroidal anti-inflammatory drug. Table 2Quantitative characteristics of 83 patients with bullous diseases treated in hospitalVariableMedian (IQR) or mean (SD)MinimumMaximumHospital stay (days)11.0 (7.0–18.0)2.054.0Age (years)75.0 (61.0–85.0)18.0102.0Haemoglobin (mg dL−1)12.9 (2.23)8.0016.90Leucocyte count (mm3)9914 (3327)1015.017 310.0Platelet count (G L−1)283.0 (235.0–370.0)31.8818.0Eosinophil count (mm3)260.0 (50.0–670.0)0.06420.0C-reactive protein (mg dL−1)2.00 (0.45–3.92)0.0519.50Alanine transferase (U L−1)23.0 (21.8)4.30136.50Aspartate transferase (U L−1)19.4 (10.0)7.860.6Gamma glutaryl transferase (U L−1)26.5 (15.0–40.0)11.0289.0Alkaline phosphatase (U/L−1)96.2 (54.0)40.0343.0Urea (mg dL−1)26.00 (19.60–41.80)8.00124.10Creatinine (mg dL−1)0.89 (0.70–1.08)0.303.30Lactate dehydrogenase (U L−1)190.5 (164.0–260.5)97.0693.0Glycaemia (mg dL−1)122.0 (40.4)72.0265.0Bicarbonate (mEq/dL−1)25.9 (4.9)16.530.9Sodium (mEq/dL−1)139.0 (5.9)115.0158.0Potassium (mEq/dL−1)4.18 (0.52)2.545.41IQR, interquartile range. Quantitative characteristics of 83 patients with bullous diseases treated in hospital IQR, interquartile range. The most common treatments were medium-potency topical steroids (n = 38; 46%) and systemic steroids (n = 50), with doses ranging from 20 to 50 mg. Hospital stay was prolonged (>10 days) in 58% (n = 48) of patients, with a median of 11 days. There was only one admission to the intensive care unit and one death (1% each). Prolonged vs. nonprolonged hospital stay When comparing prolonged and nonprolonged hospital stays (Table 3), palmoplantar and genital mucosal involvement was significantly more frequent in prolonged stays; eosinophilia, liver enzyme abnormalities, the use of high-potency steroids and elevated C-reactive protein were also present, and those who required opioids or antibiotics during hospitalization tended to have longer stays. It is noteworthy that pemphigus foliaceus was more frequent among those who did not have a prolonged hospital stay. It is also important to note that six patients had genital mucosa involvement and these six had a prolonged hospital stay. A single case of hypotension was identified, and this patient also had a prolonged hospital stay. Table 3Patient characteristics according to prolonged or nonprolonged hospital stayCharacteristicsHospital stay, n (%) P-valueaPR (95% CI)Prolonged (n = 48)Nonprolonged (n = 35)History variables Biologic sex Female33 (69)18 (51)0.111 Male15 (31)17 (49)0.72 (0.47–1.10) DDP4 inhibitor Yes3 (6)7 (20)0.061 No45 (94)28 (80)2.05 (0.78–5.38) Diuretics Yes4 (8)6 (17)0.221 No44 (92)29 (83)1.50 (0.68–3.29) Antibiotics Yes8 (17)6 (17)0.951 No40 (83)29 (83)1.01 (0.61–1.66) Anticonvulsants Yes2 (4)1 (3)0.751 No46 (96)34 (97)0.86 (0.37–1.96) NSAIDs No45 (94)35 (100)0.131 Yes3 (6)0 (0)1.77 (1.46–2.15) Opioids No46 (96)35 (100)0.221 Yes2 (4)0 (0)1.76 (1.45–2.12) History of neoplasia No45 (94)33 (94)0.921 Yes3 (6)2 (6)1.04 (0.49–2.18) Haematological malignancy No47 (98)34 (97)0.821 Yes1 (2)1 (3)0.86 (0.21–3.48) Solid organ malignancy No46 (96)33 (94)0.751 Yes2 (4)2 (6)0.85 (0.31–2.32) History of recent infection No40 (83)27 (77)0.481 Yes8 (17)8 (23)0.83 (0.49–1.42) History of arterial hypertension No20 (42)12 (34)0.491 Yes28 (58)23 (66)0.87 (0.60–1.26) History of diabetes mellitus No33 (69)19 (54)0.171 Yes15 (31)16 (46)0.76 (0.50–1.15) History of hypothyroidism No41 (85)31 (89)0.681 Yes7 (15)4 (11)1.11 (0.68–1.82) History of dyslipidaemia No30 (63)22 (63)0.971 Yes18 (38)13 (37)1.00 (0.68–1.47) History of obesity No32 (67)27 (77)0.291 Yes16 (33)8 (23)1.22 (0.85–1.77) History of neurological disease No32 (67)27 (77)0.291 Yes16 (33)8 (23)1.22 (0.85–1.77) History of psychiatric illness No37 (77)26 (74)0.761 Yes11 (23)9 (26)0.93 (0.59–1.46) History of autoimmune disease No46 (96)32 (91)0.411 Yes2 (4)3 (9)0.67 (0.22–2.01)Clinical variables Bullous pemphigoid No20 (42)18 (51)0.371 Yes28 (58)17 (49)1.18 (0.81–1.72) Pemphigus foliaceus No44 (92)26 (74) 0.031 Yes4 (8)9 (26)0.48 (0.21–1.12) Pemphigus vulgaris No35 (73)29 (83)0.281 Yes13 (27)6 (17)1.25 (0.85–1.82) IgA pemphigus No47 (98)34 (97)0.821 Yes1 (2)1 (3)0.86 (0.21–3.48) Acquired epidermolysis bullosa No47 (98)35 (100)0.391 Yes1 (2)0 (0)1.74 (1.44–2.10) Linear IgA dermatosis No47 (98)34 (97)0.821 Yes1 (2)1 (3)0.86 (0.21–3.48) Percentage of body surface area <30%25 (52)22 (63)0.291 >60%4 (8)2 (6)1.25 (0.67–2.34) 30–60%18 (38)8 (23)1.30 (0.89–1.88) No data1 (2)3 (9)0.47 (0.08–2.62) Weals No33 (69)30 (86)0.071 Yes15 (31)5 (14)1.43 (1.01–2.02) Eczematous lesions No29 (60)21 (60)0.961 Yes19 (40)14 (40)0.99 (0.68–1.44) Desquamation No26 (54)21 (60)0.591 Yes22 (46)14 (40)1.10 (0.76–1.59) Scalp involvement No35 (73)27 (77)0.661 Yes13 (27)8 (23)1.09 (0.73–1.63) Oral mucosa involvement No33 (69)27 (77)0.391 Yes15 (31)8 (23)1.18 (0.81–1.72) Conjunctiva involvement No45 (94)35 (100)0.131 Yes3 (6)0 (0)1.77 (1.46–2.15)Genital mucosa involvement No42 (88)35 (100) 0.031 Yes6 (13)0 (0)1.83 (1.49–2.24) Palmoplantar involvement No38 (79)33 (94) 0.05 1 Yes10 (21)2 (6)1.55 (1.11–2.17) Impetiginization No43 (90)34 (97)0.191 Yes5 (10)1 (3)1.49 (0.99–2.24) Hypotension No47 (98)35 (100)0.391 Yes1 (2)0 (0)1.74 (1.44–2.10)Laboratory variables Haemoglobin No anaemia33 (69)22 (63)0.461 Anaemia15 (31)12 (34)0.92 (0.62–1.38) White blood cell count Leucopenia3 (6)1 (3)0.4851 Normal13 (27)7 (20)0.86 (0.45–1.66) Leucocytosis32 (67)26 (74)0.73 (0.39–1.35) Platelet count Thrombocytopenia1 (2)1 (3)0.7511 Normal38 (79)30 (86)1.11 (0.27–4.54) Thrombocytosis8 (17)3 (9)1.45 (0.34–6.09) Eosinophil count Normal26 (54)23 (66) 0.0061 Eosinophilia21 (44)6 (17)1.46 (1.05–2.04) Alanine transferase Normal43 (90)23 (66) 0.031 Elevated1 (2)3 (9)0.38 (0.06–2.11) Aspartate transferase Normal41 (85)25 (71) 0.031 Elevated4 (8)1 (3)1.28 (0.79–2.07) Gamma glutaryl transferase Normal2 (4)7 (20) 0.021 Elevated5 (10)0 (0)4.5 (1.32–15.2) Alkaline phosphatase Normal23 (48)5 (14) 0.0011 Elevated3 (6)0 (0)1.21 (1.02–1.44) Urea Normal25 (52)16 (46)0.831 Elevated9 (19)7 (20)0.92 (0.56–1.51) Creatinine Normal38 (79)18 (51) 0.021 Elevated10 (21)15 (43)0.58 (0.35–0.98) Lactate dehydrogenase Normal8 (17)4 (11)0.131 Elevated7 (15)1 (3)1.31 (0.81–2.11) Glycaemia Normal9 (19)3 (9) 0.07 1 Hyperglycaemia18 (38)8 (23)0.92 (0.60–1.39) Bicarbonate Diminished1 (2)2 (6)0.471 Normal1 (2)0 (0)3 (0.60–14.8) Elevated4 (8)1 (3)2.4 (0.45–12.6) Serum sodium Hyponatraemia4 (8)2 (6)0.091 Normal31 (65)14 (40)1.03 (0.56–1.88) Hypernatraemia1 (2)2 (6)0.5 (0.09–2.72) Serum potassium Hypokalaemia4 (8)1 (3)0.321 Normal29 (60)17 (49)0.78 (0.48–1.28) Hyperkalaemia3 (6)2 (6)0.75 (0.32–1.73)Treatment variables Topical steroid High potency27 (56)7 (20) 0.0051 Low potency0 (0)2 (6)INDb Medium potency19 (40)19 (54)0.62 (0.43–0.90) Not received1 (2)5 (14)0.20 (0.03–1.26) In-hospital opioids No33 (69)32 (91) 0.03 1 Yes14 (29)2 (6) 1.72 (1.27–2.33) In-hospital antibiotics No25 (52)29 (83) 0.01 1 Yes22 (46)5 (14) 1.76 (1.25–2.47) CI, confidence interval; DPP4, dipeptidyl peptidase-4; IND, indeterminable; NSAID, nonsteroidal anti-inflammatory drug; PR, prevalence ratio.aStastistically significant values in bold.bIndeterminate with this values. Patient characteristics according to prolonged or nonprolonged hospital stay CI, confidence interval; DPP4, dipeptidyl peptidase-4; IND, indeterminable; NSAID, nonsteroidal anti-inflammatory drug; PR, prevalence ratio. Stastistically significant values in bold. Indeterminate with this values. Multivariate analysis Those who did not use DPP4 inhibitors showed a significant association with a higher probability of prolonged stay [adjusted prevalence ratio (aPR) 8.56, 95% CI 1.46–50.26; P = 0.02]. Eosinophilia was also significantly associated (aPR 5.40, 95% CI 1.28–22.65; P = 0.02) with a prolonged hospital stay (Table 4). In-hospital antibiotic use remained an associated factor (aPR 3.75, 95% CI 1.01–13.95; P = 0.05). However, although variables such as opioid use and palmoplantar involvement were significant in the bivariate analysis, they did not maintain adjusted significance. For this reason, the factors associated with the highest probability of stay were not using previous DPP4, presence of eosinophilia and receiving hospital antibiotics. Variables not previously mentioned did not maintain adjusted significance. Table 4Multivariate analysisCharacteristics P-valueaPR (95% CI) P-valuebaPR (95% CI)Biologic sex Female0.1110.921 Male0.72 (0.47–1.10)0.94 (0.30–2.97)DDP4 inhibitor Yes0.061 0.02 1 No2.05 (0.78–5.38)8.56 (1.46–50.26)Palmoplantar involvement No 0.05 10.451 Yes1.55 (1.11–2.17)2.02 (0.33–12.44)Eosinophil count Normal 0006 1 0.02 1 Eosinophilia1.46 (1.05–2.04)5.40 (1.28–22.65)In-hospital opioids No 0.03 10.211 Yes1.72 (1.27–2.33)3.06 (0.53–17.5)In-hospital antibiotics No 0.01 1 0.05 1 Yes1.76 (1.25–2.47)3.75 (1012–13.95)Bold denotes statistical significance. aPR, adjusted prevalence ratio; CI, confidence interval; DPP4, dipeptidyl peptidase-4 ; PR, prevalence ratio.aOriginal bivariate P-value.bAdjusted multivariate P-value. Multivariate analysis Bold denotes statistical significance. aPR, adjusted prevalence ratio; CI, confidence interval; DPP4, dipeptidyl peptidase-4 ; PR, prevalence ratio. Original bivariate P-value. Adjusted multivariate P-value. Profile analysis Within the profile analysis, patients with a nonprolonged hospital stay tended to be men, did not present genital mucosa and palmoplantar involvement, had used DPP4 inhibitors and did not have eosinophilia. Patients with prolonged stays were women, had normal and elevated alkaline phosphatase, in addition to eosinophilia, hypotension and palmoplantar involvement, and not having alanine transferase elevations. Contributor Information Pedro Juan Saldarriaga-Muñoz, Dermatology Service, Universidad CES, Medellín, Colombia. Valentina Rodelo-Sánchez, Dermatology Service, Universidad CES, Medellín, Colombia. Isabela Agudelo-Aguilar, Dermatology Service, Universidad CES, Medellín, Colombia. David Osorio-Álvarez, Plastic Surgery Service, Clínica CES, Medellín, Colombia. Sebastián Valencia-Montoya, Universidad CES, Medellín, Colombia. Sebastián Bedoya-Mejía, Universidad CES, Medellín, Colombia. Susana Chiquito-García, Dermatology Service, Universidad CES, Medellín, Colombia; Dermatology Service, Clínica CES, Medellín, Colombia. Geovanna Andrea Ayala-Monroy, Dermatology Service, Universidad CES, Medellín, Colombia; Dermatology Service, Clínica CES, Medellín, Colombia. Discussion AIBDs accounted for 2.8% of dermatology consultations (n = 83/3000). In general, these diseases are infrequent, with pemphigus vulgaris and pemphigoid being the main ones, with a prevalence of between 0.38 and 30 cases per 100 000 people per year for the former and 1.46 to 47.99 cases per 100 000 for the latter.11–15 In a cross-sectional study from Khartoum, pemphigus vulgaris was the most common autoimmune blistering disorder (32.6%) and BP the second most common (29.3%), with a female predominance (58.7%); by contrast, in our cohort, BP was seen most frequently (54.2%), while the female predominance was concordant (61.4%).16 The number of cases reported is comparable to that reported by Camacho-Pérez et al., where 21 patients with pemphigus were evaluated over a 5-year period, and Zuluaga et al., with 99 cases of pemphigus and pemphigoid over 16 years.17,18 Although no hospital-stay studies have been carried out for AIBDs as a group, Ren et al. reported an average hospital stay of 7.3 days for BP in addition to a mortality rate of 2.3%, comparable to the median of 11 days and mortality rate of 1.2% reported in the present study, even including other bullous pathologies such as pemphigus foliaceus which, due to its smaller spread, limitation to seborrhoeic areas and absence of mucosal involvement, is associated with shorter stays.3 Additionally, it was clearly observed that there is marked metabolic and cardiovascular comorbidity due to hypertension, diabetes and dyslipidaemia, with results similar to those reported by Sánchez-García et al., as well as other studies that evaluated comorbidity.19,20 While this can be partly explained by the presentation of these diseases in older individuals, it also implies that they are patients at higher risk of a major cardiovascular event.21,22 The association of the use of DPP4 inhibitors with shorter hospital stays is also highlighted. In the last 10 years, the relationship between the use of this group of drugs and the development of BP has been identified.23,24 Considering that BP is associated with longer hospital stays and refractoriness in treatment, this association can be interpreted as meaning that in patients with an associated drug trigger, withdrawal of this drug implies a faster response to hospital management. In contrast to the most relevant clinical characteristics, the involvement of the genital mucosa and palmoplantar involvement stands out. Although these areas may not represent large body surfaces, they imply areas of great morbidity and limitation, which may explain the prolongation of the hospital stay.25–29 In a retrospective study by Garrido et al., a relationship was found between elevated serum eosinophil levels and palmoplantar involvement, which may partly support the association of involvement in this anatomical area with prolonged hospital stay.30 Regarding the paraclinical findings associated with prolonged hospital stay, the importance of eosinophilia should be highlighted due to its sustained significance in the multivariate analysis. Given that more than half of patients in our study were diagnosed with BP, it is coherent with the predominance of eosinophilia. Consistent with the results of a prior retrospective cohort study, the requirement for inpatient care was significantly associated with higher baseline peripheral blood eosinophil counts, and relapse was more frequent among patients presenting with higher eosinophil levels. Peripheral eosinophil counts also correlated with circulating anti-BP180 IgG and IgE titres and with overall disease severity, supporting the biologic plausibility of an eosinophil-driven, type-2 inflammatory endotype in BP.30–33 Although the correlation between these specific variables was not assessed, they could correspond to the reason behind the need to extend the stay. Among the other laboratory variables, liver enzymes of both hepatocellular and cholestatic patterns stand out, as does the elevation of C-reactive protein. Regarding liver enzymes, the literature reports elevations associated with the use of immunosuppressive treatment, as well as a case of paraneoplastic pemphigus secondary to hepatocarcinoma.34,35 None of these situations would explain the elevations in the cases presented and as such they could represent a sign of comorbidity or even damage associated with the same pathology, although there are no current data to support this theory. However, an elevation in C-reactive protein has been correlated with the activity of bullous disease, reflecting the underlying inflammatory process, and can be a confounding factor in the face of an underlying infectious process, so it must be evaluated over time.36–39 Elhag et al. conducted a cross-sectional study at the Khartoum Dermatology and Venereal Diseases Hospital, providing supportive evidence of the positive role of complement components, particularly C3, in diagnosing pemphigus, with a good correlation with disease severity. As our study did not include IgG or complement levels among the variables analysed, we did not perform an exhaustive search for an association between these variables and prolonged hospital stay. However, these markers could prove useful in assessing the prognosis of patients with AIBDs.16 The use of hospital antibiotics is highlighted as a factor associated with prolonged stay. Patients with blistering diseases, having a compromised skin barrier, are more susceptible to developing infections in both the ambulatory and nosocomial settings.3,6,22,40 A retrospective study of hospitalized patients with pemphigus at Peking University First Hospital found that those with bacterial skin infections had a significantly longer duration of stay than those without infections (median 18.9 vs. 14.1 days).41 Careful management of isolation and protection measures can impact the development of these infections and prolong stays due to the need for antibiotic use. Systemic corticosteroids are the cornerstone of treatment for severe blistering diseases, including in hospitalized patients. However, when steroid monotherapy fails to achieve adequate disease control or is contraindicated because of patient comorbidities, adjunctive therapies can be added, such as steroid-­sparing agents, antibiotics, ciclosporin, mycophenolate mofetil, rituximab and intravenous immunoglobulin. Nonetheless, the disease in a subset of patients remains refractory or patients experience significant adverse effects, which has driven the development of targeted therapies based on a more advanced understanding of the pathophysiology of these conditions. Emerging options include dupilumab, omalizumab, anti-eosinophil strategies, complement-directed therapies, Janus kinase inhibitors and FcRn antagonists, which have shown effectiveness and offer a path towards reducing the toxicity associated with broad immunosuppressive regimens; however, although studies are underway, there is still no published evidence specifically documenting their use in hospitalized patients, and well-designed trials are needed to evaluate their efficacy and safety in these settings.42,43 The main limitation of this retrospective study is the use of a secondary source for data collection, which can introduce information bias due to the lack of homogeneity in the recording of clinical and paraclinical parameters. Additionally, not all patients had the same laboratory tests available, which could limit the generalizability of certain findings. However, laboratory and pathology results were retrieved directly from the institutional system, minimizing the risk of interpretive bias from treating physicians. This bias was also reduced through standardization in the ­data-collection process during a pilot test. Taking this into account, this study continues to have external validity as it represents a census of the evaluated population, which can be extrapolated to other institutions with hospital dermatology services. The present study highlights how most patients with AIBDs bullous diseases have prolonged hospital stays, which implies higher costs and increased risk of infection and adverse outcomes. The evaluation of triggering factors, such as the use of DPP4 inhibitors, for early discontinuation may impact this outcome. In addition, the importance of evaluating the mucous membranes and the palmoplantar region as possible predictors of prolonged stay is highlighted. In addition to this, basic investigations that include a blood count, liver enzymes and inflammatory markers are undertaken to identify patients who are most likely to have prolonged stays. Finally, cautious biosecurity measures must be taken to avoid infections that negatively impact the hospital stay, and morbidity and mortality of these patients. In the future, we suggest conducting prospective studies in which clinimetric assessments, laboratory tests and histopathological reporting are standardized. This would better establish causality and the predictive role of these factors in prolonged hospital stays. Author contributions Pedro Juan Saldarriaga-Muñoz (Conceptualization [lead], Data curation, Investigation, Validation, Writing—original draft [equal]), Valentina Rodelo-Sánchez (Data curation, Investigation, Writing—original draft [equal]), Isabela Agudelo-Aguilar (Data curation, Investigation, Writing—original draft [equal]), David Osorio-Álvarez (Data curation, Investigation, Writing—original draft [equal]), Sebastián Valencia-Montoya (Data curation, Investigation, Writing—original draft [equal]), Sebastián Bedoya-Mejía (Conceptualization, Formal analysis, Methodology, Writing—original draft [equal]), Susana Chiquito-García (Conceptualization, Investigation, Super­vision, Writing—review & editing [equal]), and Geovanna Andrea Ayala-Monroy (Conceptualization, Data curation, Investi­gation, Supervision, Writing—review & editing [equal]) Funding sources This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. Conflicts of interest The authors declare no conflicts of interest. Data availability The data underlying this article will be shared on reasonable request to the corresponding author. Ethics statement The study protocol was reviewed by the Ethics Committee of Universidad CES under Act No. 229 (2023) and was considered a minimal-risk study. According to Colombian legislation, resolution 8430 of 1993, it is considered risk-free research. Patient consent Not applicable. References Associated Data Data Availability Statement The data underlying this article will be shared on reasonable request to the corresponding author.